HealthEquity, Inc
HQY
$91.90
+0.93%
HealthEquity, Inc. is a leading administrator of tax-advantaged healthcare savings accounts, primarily Health Savings Accounts (HSAs), along with consumer-directed benefits such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and COBRA administration, operating within the healthcare information services industry. The company is distinct as the largest non-bank HSA custodian in the United States, functioning as a platform that connects employers, health plans, and members while earning fee-based revenue on assets under administration and interchange. The current investor narrative centers on the company's ability to sustain double-digit revenue growth and margin expansion amid a maturing HSA market, with recent attention focused on its Q2 FY2027 earnings beat that was overshadowed by conservative full-year guidance, which management attributed to macroeconomic uncertainty and slower account growth. Additionally, the stock has been under pressure due to a sharp sell-off in late August 2026, reflecting investor disappointment over the guidance and concerns about competitive dynamics and interest rate sensitivity on custodial cash balances.…
HQY
HealthEquity, Inc
$91.90
Related headlines
Investment Opinion: Should I buy HQY Today?
Based on the synthesis of analyst consensus, valuation, and growth prospects, HQY earns a Buy rating for long-term investors, but with caution. The core thesis is that the stock is undervalued on a forward basis (forward PE of 16.37x) relative to its expected earnings growth (estimated EPS of $5.98 next year), and the strong buy consensus with an average target of $119.33 implies 32.5% upside. The recent sell-off appears overdone given the company's robust margins and cash flow.
The supporting evidence is compelling: revenue grew 7.64% year-over-year in Q2 FY2027, gross margin expanded to 73.55% from 62.41% in Q3 FY2025, operating margin improved to 28.14%, and free cash flow was $471.67 million TTM. The balance sheet is healthy with a current ratio of 3.27 and debt-to-equity of 0.48. The forward PE of 16.37x is below the sector average, and the PEG ratio of 0.27 suggests undervaluation relative to growth. Analyst estimates for revenue ($1.61 billion) and EPS ($5.98) imply continued expansion.
However, risks could invalidate the thesis. Revenue growth is decelerating, and the recent guidance cut highlights sensitivity to macroeconomic factors and competition. The trailing PE of 34.27x is above the sector, leaving room for multiple compression if growth slows further. The stock would upgrade to a Strong Buy if revenue growth reaccelerates above 10% and margins continue to expand, or downgrade to a Hold if growth falls below 5% or if interest rate declines significantly impact custodial revenue. Relative to its history, the PS ratio of 5.62x is near the low end of its range (18.79x to 30.70x? Actually, that range seems off; the PS ratio historically has been much higher, but current 5.62x is low), suggesting the stock is undervalued compared to its own past. Overall, HQY appears undervalued on a forward basis and offers a favorable risk/reward for patient investors.
Sign up to view all
HQY 12-Month Price Forecast
HealthEquity presents a balanced risk/reward profile. The stock is undervalued on a forward basis, with a forward PE of 16.37x and a PEG ratio of 0.27, suggesting the market underestimates its earnings growth. However, revenue growth is decelerating, and the recent guidance cut has dampened sentiment. The strong analyst consensus and low beta make it a defensive holding, but the premium trailing valuation and competitive pressures warrant caution. I would upgrade to bullish if revenue growth reaccelerates above 10% and margins continue to expand, or downgrade to bearish if growth falls below 5% or if interest rate cuts significantly impact custodial revenue.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $119.33 and implied upside of +29.9% versus the current price.
Average Target
$119.33
0 analysts
Implied Upside
+29.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $142
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of strong buy and a recommendation mean of 1.33 (where 1 is a strong buy and 5 is a strong sell). The average target price is $119.33, which implies a 32.5% upside from the current price of $90.04. The consensus is decidedly bullish, with no sell ratings and a strong buy consensus, indicating that analysts see significant value in the stock despite recent underperformance. The estimated EPS average for the next fiscal year is $5.98, with a range of $5.38 to $6.42, and estimated revenue average of $1.61 billion, ranging from $1.58 billion to $1.65 billion. The high target price of $142.00 would represent a 57.7% upside and likely assumes successful execution on margin expansion, new account growth, and possibly multiple expansion as the market recognizes the company's earnings power. The low target of $105.00 still implies a 16.6% upside, suggesting that even the most conservative analysts see the stock as undervalued, with the low target likely pricing in slower growth but stable margins. The wide range between the low and high targets ($37.00) signals moderate uncertainty, but the fact that all targets are above the current price indicates strong conviction in the company's fundamentals. Recent institutional ratings show mostly reiterations of Buy or Outperform ratings, with BMO Capital upgrading from Market Perform to Outperform on April 9, 2026, and no downgrades in the past six months. This pattern of stable to improving ratings, combined with the recent price weakness, suggests that analysts are becoming more confident even as the stock has sold off, which could be a positive contrarian signal.
Drowning in data?
Find the real signal!
Bulls vs Bears: HQY Investment Factors
The bull case for HealthEquity rests on its strong analyst support, attractive forward valuation, expanding margins, and defensive low-beta profile. The bear case centers on decelerating revenue growth, recent stock underperformance, premium trailing valuation, and sensitivity to interest rates and competition. Currently, the bear evidence appears stronger in the short term, given the stock's 8.63% monthly decline and guidance disappointment, but the bull case has substantial merit for longer-term investors. The single most important tension is whether the company can reaccelerate revenue growth and sustain margin expansion to justify the optimistic forward earnings estimates. If growth stabilizes and the forward PE of 16.4x proves too low, the stock could re-rate sharply; conversely, if growth continues to slow, the premium trailing multiple could compress further.
Bullish
- Strong Buy Consensus with 32.5% Upside: All 15 covering analysts rate HQY a strong buy (recommendation mean 1.33), with an average target price of $119.33 implying 32.5% upside from $90.04. Even the lowest target of $105.00 offers 16.6% upside, indicating that analysts see a margin of safety at current levels.
- Forward PE of 16.4x Is Attractive: The forward PE of 16.37x is well below the trailing PE of 34.27x and the broader healthcare information services sector (typically low-to-mid 20s). This discount suggests the market is pricing in significant earnings growth (estimated EPS of $5.98 next year) that may be underappreciated.
- Margin Expansion and Cash Generation: Gross margin improved to 73.55% in Q2 FY2027 from 62.41% in Q3 FY2025, while operating margin rose to 28.14% from 24.79%. Free cash flow was $135.18 million in the quarter and $471.67 million TTM, demonstrating robust cash conversion.
- Low Beta Provides Defensive Characteristics: With a beta of 0.225, HQY is only about 22.5% as volatile as the broader market. This low correlation could offer downside protection in turbulent markets, making it suitable for risk-averse investors seeking healthcare exposure.
Bearish
- Revenue Growth Decelerating: Q2 FY2027 revenue grew 7.64% year-over-year, down from 8.7% in the prior-year period, and revenue declined sequentially from $354.64 million in Q1 to $350.73 million in Q2. This deceleration, combined with conservative full-year guidance, has raised concerns about the company's growth trajectory.
- Recent Stock Underperformance: HQY has declined 8.63% over the past month and 5.53% over three months, significantly underperforming the S&P 500's gains of 0.59% and 3.34%, respectively. The relative strength of -9.22% over one month indicates stock-specific weakness beyond market-wide movements.
- Valuation Premium on Trailing Basis: The trailing PE of 34.27x is above the sector average in the low-to-mid 20s, and the PS ratio of 5.62x exceeds the sector median of 3-4x. This premium may be difficult to sustain if growth continues to moderate.
- Interest Rate Sensitivity on Cash Balances: As the largest non-bank HSA custodian, HQY earns income on custodial cash balances, which are sensitive to interest rate changes. The recent guidance cut was partly attributed to macroeconomic uncertainty, highlighting vulnerability to rate movements.
HQY Technical Analysis
HQY is in a broad recovery phase, having gained 0.40% over the past year, but it remains 16.3% below its 52-week high of $107.62 and 23.7% above its 52-week low of $72.76, placing the current price of $90.04 at roughly 50.3% of its 52-week range. This mid-range positioning suggests a market that is neither overly optimistic nor deeply pessimistic, but rather in a consolidation pattern following a significant drawdown from the highs. The stock's 1-year change of 0.40% lags the S&P 500's 15.01% gain, indicating relative weakness and a lack of sustained momentum. Over the past month, HQY has declined 8.63%, while the S&P 500 rose 0.59%, resulting in a relative strength of -9.22%, which signals a sharp deceleration in short-term momentum. The 3-month change of -5.53% also underperforms the S&P 500's 3.34% gain, with a relative strength of -8.87%, confirming that the recent pullback is not just a market-wide phenomenon but a stock-specific underperformance. The 6-month change of +6.34% is positive but still trails the S&P 500's 17.35% gain, highlighting that the stock has been a laggard even during periods of broader market strength. This divergence between the longer-term recovery and the recent negative momentum could indicate a trend reversal or a temporary pullback driven by the August guidance disappointment. Key technical levels to watch include support at the 52-week low of $72.76, which if breached could trigger further selling, and resistance at the 52-week high of $107.62, a breakout above which would signal renewed bullish momentum. The stock's beta of 0.225 is remarkably low, indicating that it is only about 22.5% as volatile as the broader market, which is unusual for a healthcare information services company and suggests defensive characteristics. This low beta implies that the stock may not participate fully in market rallies but could also provide downside protection, making it suitable for risk-averse investors. The current price of $90.04 is above the 52-week low but well below the high, and the recent decline from the August peak of $105.41 to $90.04 represents a 14.6% drop, underscoring the severity of the recent sell-off.
Beta
0.24
0.24x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$73-$108
Price range past year
Annual Return
+3.8%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -4.3% | +0.9% |
| 3m | -3.1% | +3.4% |
| 6m | +17.9% | +14.4% |
| 1y | +3.8% | +16.2% |
| ytd | +0.9% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
HealthEquity's revenue trajectory remains positive but is decelerating, with Q2 FY2027 revenue of $350.73 million representing a 7.64% year-over-year increase, down from the 8.7% growth seen in the prior-year period. The most recent quarter's revenue of $350.73 million was slightly below Q1 FY2027's $354.64 million, indicating a sequential decline that may reflect seasonal factors or slowing account growth. Over the past four quarters, revenue has grown from $322.16 million in Q3 FY2026 to $334.59 million in Q4 FY2026, $354.64 million in Q1 FY2027, and $350.73 million in Q2 FY2027, showing a general upward trend but with some volatility. The revenue segments show a diversified mix, with Financial Service, Other contributing $175.94 million, Service $124.44 million, and Credit and Debit Card $50.35 million, but the lack of period-over-period segment data limits deeper analysis. The growth rate of 7.64% is solid but not spectacular, and the market's negative reaction to guidance suggests that investors expect faster growth, possibly from new product offerings or acquisitions. Profitability is robust, with Q2 FY2027 net income of $65.64 million and a net margin of 18.72%, up from 16.05% in the prior-year quarter. The gross margin for Q2 FY2027 was 73.55%, a significant improvement from 62.41% in Q3 FY2025, reflecting operating leverage and a shift toward higher-margin service revenue. Operating margin stood at 28.14% in Q2 FY2027, compared to 24.79% in Q3 FY2025, indicating consistent margin expansion. The company's EBITDA for Q2 FY2027 was $142.43 million, with an EBITDA margin of 40.61%, up from 37.36% in Q3 FY2025, demonstrating strong cash generation. These margin improvements are notable and suggest that management's cost control initiatives and scale benefits are paying off, which could support earnings growth even if revenue growth moderates. The balance sheet is healthy, with a current ratio of 3.27 and a debt-to-equity ratio of 0.48, indicating ample liquidity and moderate leverage. Free cash flow for the trailing twelve months was $471.67 million, and in Q2 FY2027 alone, free cash flow was $135.18 million, representing a strong conversion of net income. The company's ROE of 10.21% and ROA of 6.65% are respectable for the industry, though not exceptional. With cash and equivalents of $256.00 million at the end of Q2 FY2027 and no dividend, the company retains earnings to fund growth and share repurchases, having bought back $107.74 million in stock during the quarter. The debt-to-equity ratio of 0.48 is manageable, and interest coverage of 7.83x (based on operating income of $98.69 million and interest expense of $12.61 million) suggests the company can comfortably service its debt. Overall, the financial health is strong, with consistent free cash flow generation and a solid liquidity position.
Quarterly Revenue
$350732000.0B
2026-07
Revenue YoY Growth
+7.6%
YoY Comparison
Gross Margin
73.6%
Latest Quarter
Free Cash Flow
$471668000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Since HealthEquity reported positive net income of $65.64 million in Q2 FY2027, the PE ratio is the appropriate primary valuation metric. The trailing PE ratio is 34.27x, while the forward PE is 16.37x, implying that the market expects significant earnings growth in the coming year. This large gap between trailing and forward PE suggests that analysts anticipate a substantial increase in EPS, likely driven by margin expansion and revenue growth, as reflected in the estimated EPS average of $5.98 for the next fiscal year. The forward PE of 16.37x is relatively low for a company with a 7.64% revenue growth rate and expanding margins, which could indicate undervaluation if the growth materializes. Compared to the industry average, HealthEquity's trailing PE of 34.27x is above the broader healthcare information services sector, which typically trades at a PE in the low-to-mid 20s. However, the forward PE of 16.37x is below the sector average, suggesting that on a forward basis, the stock is trading at a discount. The PS ratio of 5.62x is also above the sector median of around 3-4x, but the company's net margin of 16.38% and ROE of 10.21% justify a premium. The PEG ratio of 0.27 is very low, indicating that the stock is undervalued relative to its earnings growth rate, though this may be skewed by the low forward PE and high expected growth. Historically, HealthEquity's PE ratio has ranged from a high of 325.88x in Q3 FY2025 to a low of 25.01x in Q1 FY2027, with the current 34.27x falling in the lower half of that range. The PS ratio has ranged from 18.79x to 30.70x, and the current 5.62x is near the low end, suggesting that the stock is trading at a discount to its historical valuation. This could present a value opportunity if the company can sustain its growth and margin trajectory, but it also reflects the market's concerns about future growth and competitive pressures.
PE
34.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~142x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
HealthEquity's financial risks are moderate but noteworthy. The debt-to-equity ratio of 0.48 is manageable, but interest expense of $12.61 million in Q2 FY2027 consumes a significant portion of operating income ($98.69 million), resulting in interest coverage of 7.83x. While this is comfortable, any decline in operating income could strain coverage. The company's revenue growth is decelerating, with Q2 FY2027 growth of 7.64% down from 8.7% a year earlier, and sequential revenue declined from $354.64 million to $350.73 million. This slowdown, if persistent, could pressure margins and cash flow. Additionally, HQY relies heavily on interchange and custodial fees, which are sensitive to interest rates and account balances; a decline in rates or balances could reduce revenue. The company's net margin of 18.72% is healthy, but the trailing PE of 34.27x leaves little room for earnings misses.
Market and competitive risks are significant. The stock trades at a premium trailing PE of 34.27x compared to the sector's low-to-mid 20s, and a PS ratio of 5.62x versus the sector median of 3-4x. If growth fails to meet expectations, multiple compression could occur. The HSA market is maturing, and competition from banks and other administrators could erode HQY's market share and pricing power. The recent guidance cut, attributed to macroeconomic uncertainty and slower account growth, highlights these pressures. With a beta of only 0.225, the stock is defensive, but this also means it may lag in strong bull markets. Regulatory changes to tax-advantaged accounts or healthcare policy could disrupt the business model. The August 2026 sell-off, where the stock dropped 14.6% from its peak of $105.41 to $90.04, underscores how quickly sentiment can shift.
The worst-case scenario for HQY would involve a combination of accelerating revenue deceleration, margin compression, and multiple contraction. If revenue growth falls below 5% and the forward PE compresses to 15x, the stock could trade near its 52-week low of $72.76, representing a 19.2% decline from the current price of $90.04. In a more severe scenario, if the company misses earnings and analysts downgrade the stock, it could test the analyst low target of $105.00? Wait, that's above current. Actually, the 52-week low is $72.76, which is 19.2% below current. The max drawdown over the past year was -30.57%, indicating that a 30% decline from recent highs is possible. From the current price, a drop to the 52-week low would mean a loss of 19.2%, and if the stock revisits its max drawdown level, it could fall to around $62.50 (30.57% below the high of $107.62? Actually, max drawdown is -30.57% from peak, so from $107.62, a 30.57% drop is $74.72, close to the 52-week low). Thus, the realistic downside is a decline to the low $70s, or about 19-20% from current levels.
FAQ
The key risks for HQY include: 1) Financial risk: revenue growth decelerated to 7.64% in Q2 FY2027, and any further slowdown could pressure margins and cash flow. 2) Competitive risk: the HSA market is maturing, and competition from banks and other administrators could erode market share and pricing power. 3) Macro risk: as a custodian, HQY earns income on cash balances, making it sensitive to interest rate changes; the recent guidance cut cited macroeconomic uncertainty. 4) Valuation risk: the trailing PE of 34.27x is above the sector, leaving room for multiple compression if growth disappoints. These risks are ranked from highest to lowest severity, with revenue deceleration being the most immediate concern.
Our 12-month forecast for HQY includes three scenarios: Bull case (30% probability) with a target range of $119-$142, driven by revenue reacceleration and margin expansion; Base case (50% probability) with a target range of $105-$119, assuming steady growth and stable margins; Bear case (20% probability) with a target range of $72.76-$90, if growth slows and multiple compresses. The base case is most likely, hinging on the company meeting consensus estimates and the forward PE being recognized as undervalued. The average analyst target of $119.33 aligns with our base case, suggesting moderate upside from current levels.
HQY appears undervalued on a forward basis but overvalued on trailing metrics. The trailing PE of 34.27x is above the healthcare information services sector average in the low-to-mid 20s, and the PS ratio of 5.62x exceeds the sector median of 3-4x. However, the forward PE of 16.37x is below the sector, and the PEG ratio of 0.27 indicates the stock is cheap relative to its growth rate. The market is pricing in significant earnings growth (estimated EPS of $5.98 next year), and if the company delivers, the stock could re-rate higher. Compared to its own history, the PS ratio is near the low end of its range, suggesting a discount to historical valuation.
From a risk/reward perspective, HQY appears attractive for long-term investors. The stock trades at $90.04, with a forward PE of 16.37x and a PEG ratio of 0.27, suggesting undervaluation relative to expected earnings growth. Analyst consensus is a strong buy with an average target of $119.33, implying 32.5% upside. However, the biggest downside risk is a continued deceleration in revenue growth, which could push the stock toward its 52-week low of $72.76 (19.2% below current). For investors with a medium to long-term horizon and tolerance for moderate volatility, HQY is a good buy at current levels, but it may not be suitable for short-term traders due to recent negative momentum.
HQY is more suitable for long-term investment due to its low beta (0.225), essential service nature, and steady cash flow generation. The company does not pay a dividend, so returns depend on capital appreciation. Earnings visibility is moderate, with analyst estimates for EPS of $5.98 next year. Short-term trading is less attractive given the recent negative momentum (down 8.63% in the past month) and the stock's low volatility, which may limit quick gains. A suggested minimum holding period is 2-3 years to allow for growth reacceleration and multiple expansion. Investors should monitor quarterly earnings for signs of a turnaround.
